Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
A large trial for pulmonary fibrosis will run until 2027
-
A large trial of inhaled treprostinil for pulmonary fibrosis is enrolling patients
-
A review of calcium disorders and a study on kidney fibrosis are in progress
A major trial for pulmonary fibrosis is starting with results expected in 2027. Other studies on kidney fibrosis and calcium disorders are also underway.
Arterial Stiffness in Children and Young People With Hypertension and Chronic Kidney Disease
This trial looks at arterial stiffness (hardening of arteries) in children and young people with kidney disease. Arterial stiffness is a marker for cardiovascular risk, but this study's results are not yet available.
Impact of Acute Kidney Injury on Hospitalization Outcomes in Patients with Chronic Kidney Disease Undergoing Cardiac Procedures with Cardiopulmonary Bypass in the United States.
Acute kidney injury (AKI) after cardiac surgery may cause permanent damage. This study looks at risk in patients with pre-existing kidney disease.
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
This is an extension study for patients who completed a previous trial of zigakibart. It will monitor long-term safety in adults with IgA nephropathy.
Nephrocalcinosis Following Roux-en-Y Gastric Bypass Secondary to Suspected Enteric Hyperoxaluria: A Case Report.
Gastric bypass surgery may lead to calcium oxalate deposits in the kidney. This case report discusses risk factors for this condition.